Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody (Q86431603)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

B Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

L Chang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

I Vainshtein

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Z Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

K Streicher

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

M Liang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

W I White

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

S Yoo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

L Richman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

B Jallal

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

L Roskos

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Y Yao

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

14 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

26 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

483-492

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

Type I interferons (alpha/beta) in immunity and autoimmunity

26 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

How cells respond to interferons

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

The human interferon alpha species and receptors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Interferons alpha and beta as immune regulators--a new look

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Systemic sclerosis and lupus: points in an interferon-mediated continuum

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Immune Interferon in the Circulation of Patients with Autoimmune Disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Systemic lupus erythematosus: all roads lead to type I interferons

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Increased expression of 2'5'oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Interferon-alpha: a therapeutic target in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Type I interferon correlates with serological and clinical manifestations of SLE

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Presence of interferon and anti-interferon in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Type I interferon system activation and association with disease manifestations in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Economics of new oncology drug development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Trends in risks associated with new drug development: success rates for investigational drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Type I interferon: potential therapeutic target for psoriasis?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Stability and performance of a population pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.35

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23511714%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference